HIMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hims & Hers Health Inc (HIMS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock is showing strong momentum, driven by positive catalysts such as a partnership with Novo Nordisk and potential growth in the obesity treatment market. While the RSI indicates the stock is overbought, the long-term growth prospects and hedge fund buying suggest a favorable entry point for long-term investors.
The stock is in a strong uptrend with a MACD histogram of 0.745, indicating positive momentum. RSI_6 is at 81.63, signaling an overbought condition, but this is typical in strong upward trends. The stock has broken above key resistance levels, with R1 at 34.057 and R2 at 36.464, suggesting further upside potential.
Partnership with Novo Nordisk to sell Wegovy and Ozempic, boosting growth in the obesity market.
Regulatory meeting in July could enhance growth prospects beyond
Global peptide market growth, with HIMS potentially capturing $10-$19 billion in revenue by
Hedge funds are buying, with a 211.82% increase in buying activity over the last quarter.
Analysts have mixed ratings, with some lowering price targets due to near-term margin pressures and risks to 2026 guidance.
Overbought RSI suggests potential short-term pullback.
No recent insider or congress trading activity to confirm additional confidence.
No financial data available for the latest quarter, but the company is transitioning to branded GLP-1s, which is expected to drive future growth.
Analysts are mixed, with recent upgrades from Barclays and Needham citing strong growth potential and a price target of $39 and $35, respectively. However, some analysts like BofA and Jefferies remain cautious due to near-term margin pressures and execution risks.
